Table 1.
Population characteristics
| Parameter | RT Patients (n = 111) | HD Patients (n = 53) | Controls (n = 21) | P |
|---|---|---|---|---|
| Males (%) | 71 (64%) | 33 (62%) | 6 (29%) | 0.09 |
| 0.8a | ||||
| Age (years) (mean ± SD) | 55 ± 12 | 64 ± 13 | 41 ± 12 | <0.01 |
| <0.01a | ||||
| Diabetes (%) | 36 (32%) | 22 (42%) | NA | 0.26 |
| Months since RT or HD | 34 (0.4 to 323) | 32 (0.2 to 278) | NA | |
| Immunosuppression (%) | NA | |||
| tacrolimus | 58 (52%) | 0 | ||
| cyclosporin | 37 (33%) | 1 (1.9%) | ||
| mycophenolic acid | 65 (59%) | 0 | ||
| azathioprine | 36 (32%) | 0 | ||
| mTOR inhibitor | 11 (10%) | 0 | ||
| corticosteroids | 91 (82%) | 5 (9.4%) | ||
| dose of methylprednisolone (mg/kg)b | 0.05 | 0.09 | ||
| (0.01 to 0.21) | (0.03 to 0.91) |
RT, renal transplant; HD, hemodialysis; NA, not applicable.
a
Renal transplanted patients versus hemodialyzed patients.
b
Median (minimum to maximum).